References
- Prichard B.N.C., Owens C.W.L. Drug treatment of hypertension. In: Genest J., Kuchel O., Hamet P., Kantin M. eds. Hypertension, physiopathology and treatment. New York, Mc Graw-Hill, 1186–94 1983.
- Case D.B., Atlas S.A., Laragh J.H., Sealey J.E., Sullivan P.A., McKinstry D.N. Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14.225, captopril) in hypertensive patients. Progr. Cardiovasc. Dis. XXI: 195–206 1978.
- Bühler F.R. Antihypertensive actions of beta-blockers. In: Laragh J.H., Bübler F.R., Seldin D.W. eds. Frontiers in hypertension research. New York-Heidelberg-Berlin, Springer-Verlag 423–435 1981.
- Cody R.J., Laragh J.H., Atlas S.A., Case D.B. Converting enzyme inhibition to identify and treat renin-mediated or sodium-volume related forms of increased peripheral resistance in hypertension and in congestive heart failure.Journal of Hypertension 1 (Suppl 1): 77–84 1983.
- Karlberg B.E., Tolagen K. Relationships between blood pressure, age, plasma renin activity and electrolyte excretion in normotensive subjects. Scand. J. clin. Lab. Invest. 37: 521–528 1977.
- Fyhrquist., Soveri P., Puutula L., Stenman U-H. Radioimmunoassay of plasma renin activity. Clin. Chem. 22: 250–256 1976.
- McKenzie J.K., Clements J.A. Simplified radioimmunoassay for aldosterone utilizing increased antibody specificity. J. clin. Endocrinol. 38: 622–5 1974.
- Brown R.D., Swander A., McKenzie J.K. Urine aldosterone radioimmunoassay: validation of a method without chromatography. J. clin. Endocrinol. 42: 894–900 1976.
- Amundsen E., Putter J., Friberger P., Knös M., Larsbraten M., Claesson G. Methods for the determination of glandular kallikrein by means of chromogenic tripeptide substrate. In: Fuyii S., Moriya H., Suzuki T. eds. Kinins II, biochemistry, pathophysiology and clinical aspects. New York-London, Plenum Press 83–;95 1979.
- Hodsman G.P., Robertson J.I.S. Captopril: 5 years on. Br. Med. J. 287: 851–852 1983.
- Gomez H.J., Cirillo V,J., Jones K.H. The clinical pharmacology of enalapril. Journal of Hypertension 1(Suppl I): 65–70 1983.
- Brunner H.R., Waeber B., Nussberger J., Schaller M-D., Gomez H.J. Long-term clinical experience with enalapril in essential hypertension. Journal of Hypertension 1(Suppl 1): 103–107 1983.
- Karlberg B.E., Atterhög J-H, Castenfors J. et al. A comparision of atenolol and metoproplol once daily on blood pressure during rest and exercise. Drugs 25(Suppl 2): 82–83 1983.
- Andrén L., Karlberg B., Öhman P., Svensson A., Asplund J., Hansson L. Captopril and atenolol combined with hydrochlorothiazide in essential hypertension. Br. J. clin. Pharmac. 14: 107s–111s 1982.
- Jenkins A.C., McKinstry D.N. Review of clinical studies of hypertensive patients treated with captopril. Med. J. Aust. 2: XXXII–XXXVII 1979.
- Winer M., Carter C.H. Effect of enalapril (MK 421) and metoprolol on blood pressure, converting enzyme, renin and catecholamines. Clin. Pharmacol. Ther. 33: 232 (Abstr.) 1983.
- Case D.B., Atlas S.A., Laragh J.H., Sullivan P.A., Sealey J.E. Use of first-dose response or plasma renin activity to predict the long-term effect of captopril: identification of triphasic pattern of blood pressure response. J. Cardiovasc. Pharmac. 2:339–346 1982.
- Gavras H., Boillaz J., Waeber B., et al. Effects of the oral angiotensin converting enzyme inhibitor MK-421 in human hypertension. Clin. Sci. 61:281s–283s 1981.